Shares of Nordson Corp. ( NDSN ) jumped more than 15% on the back of the company posting its financial results for the fourth quarter of 2017. The company reported revenue grew 12.7% to $573.94 million. EPS came in at $1.38. The company beat earnings estimates by five cents and revenue expectations by $28.79 million.
The operating profit increased 13% to $125 million compared to the same quarter a year ago, while EBITDA increased 17% to $150 million year over year.
President and CEO Michael F. Hilton was pleased with the company's quarterly results and revenue growth. He said growth was "driven largely by robust demand in electronics end markets within the Advanced Technology segment, results for the quarter exceeded our guidance."
Guidance is solid. For the first quarter of fiscal 2018, sales are expected to increase between 30% and 34%. Moreover, the operating margin is expected to be approximately 22% and GAAP diluted EPS are expected to be in the range of $1.29 to $1.39.
Another stock with great upside movement is TevaPharmaceutical Industries Ltd. ( TEVA ). The stock jumped 14% after the company announced a restructuring plan which will reduce the workforce by 25%.
The company also announced it will suspend its dividend for ordinary shares. Dividends for mandatory convertible preferred shares will be evaluated on a quarterly basis and no annual bonuses will be paid for the current year.
"Two weeks ago we announced a new organizational structure and executive management team," President and CEO Kare Schultz said. "Today we are launching a comprehensive restructuring plan, crucial to restoring our financial security and stabilizing our business. We are taking immediate and decisive actions to reduce our cost base across our global business and become a more efficient and profitable company."
Shares of Valeant Pharmaceuticals International Inc. ( VRX ) lost more than 12% on Thursday after analysts at JPMorgan lowered the target price to $12 and downgraded its rating to underweight.
Disclosure : The author holds no positions in any stocks mentioned.
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
